Pfizer Entered into a Research Collaboration with Longevity Biotech Gero to Discover Targets for Fibrotic Diseases
Shots:
- Gero will receive an up front and is eligible to receive discovery milestones if the project moves forward
- Under the terms of collaboration, the companies will utilize Pfizer's expertise and Gero’s machine-learning technology platform to identify high-value targets for the treatment of fibrotic diseases based on large-scale human-based data
- Pfizer will be responsible to advance the potential therapeutic targets and will also lead the further preclinical and clinical development
Ref: Business Wire | Image: Pfizer
Related News:- Pfizer Reports P-III Study (BENEGENE-2) Results of Fidanacogene Elaparvovec for Hemophilia B
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
